VTRS
Viatris Inc.
NASDAQ NMS - GLOBAL MARKET· Pharmaceuticals· US· IPO 1973-02-01
$18.92
+0.25 (+1.34%)
last quote
Want the full multi-source brief on VTRS?
The agent pulls regulatory filings, news flow, prediction-market pricing, and macro context — then synthesizes what's not yet in the price.
Today
Open
$18.92
High
$18.94
Low
$18.64
Previous close
$18.67
Fundamentals
Market cap
$21.53B
P/E (TTM)
—
P/S (TTM)
1.46x
P/B
0.97x
Gross margin
40.34%
Operating margin
-0.91%
Net margin
-2.79%
Rev growth (YoY)
4.40%
EPS growth (YoY)
—
ROE
-2.79%
52W high
$19.50
52W low
$9.92
Beta
0.87x
Industry peers
by market cap
Upcoming earnings
next 30 days
2026-11-05todaybefore market
Q3 2026EPS est $0.65Rev est $3861.6M
Recent SEC filings
CIK 1792044filing-language history →
Recent news
2026-10-28 → 2026-11-04
Yahoo · 21h
Viatris Gears Up to Report Q3 Earnings: Is a Beat in the Cards?
VTRS heads into Q3 earnings with new product growth, regional sales trends and supply challenges shaping its outlook.
Yahoo · 22h
Sotera Health Company (SHC) Beats Q3 Earnings and Revenue Estimates
Sotera Health (SHC) delivered earnings and revenue surprises of +7.41% and +1.71%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Yahoo · 1d
Betting On Drug Sales: Is Viatris Or Lilly The Better Way In?
For questions about this article or underlying research, email help@trefis.com.
Yahoo · 1d
Will These 5 Drug Bigwigs Surpass Q3 Earnings Forecasts?
AMGN, PFE, MRNA, NVO and VTRS are set to report this week as recent beats and key drug demand set up a pivotal Q3 earnings test for pharma giants.
Yahoo · 4d
4 Medical Stocks With a Healthy Shot at Q3 Earnings Beats
VTRS, RVTY, ELAN and VCYT have earnings beat signals ahead of Q3 results. Can drug launches, lab spending and cancer tests overcome margin pressures?
Yahoo · 4d
Viatris Announces Commencement of Tender Offer to Acquire Pacira BioSciences, Inc.
Viatris Inc. ("Viatris") (Nasdaq: VTRS), a global healthcare company, today announced that Peach Purchaser Sub Inc. ("Purchaser"), a wholly owned subsidiary of Viatris, has commenced a tender offer to purchase all of the issued and outstanding shares of common stock, par value $0.001 per share (the "Shares"), of Pacira BioSciences, Inc. ("Pacira") (Nasdaq: PCRX), for $36.50 per Share, in cash, net
Benzinga · 5d
Viatris Subsidiary Peach Purchaser Sub Commences Tender Offer To Acquire Pacira Biosciences For $36.50/Shr
Viatris Inc. ("Viatris") (NASDAQ:VTRS), a global healthcare company, today announced that Peach Purchaser Sub Inc. ("Purchaser"), a wholly owned subsidiary of Viatris, has commenced a tender offer to
Yahoo · 5d
Why Did MA, LNG, VTRS Stocks Surge To 52-Week Highs?
Mastercard, Cheniere Energy and Viatris shares climbed to annual highs on Thursday amid strong quarterly results and positive company catalysts.
This is the free preview
The agent layer adds regulatory-language drift detection, cross-venue prediction-market signals, macro overlays, programmable alert rules, overnight briefs, and a grounding verifier on every claim. 7-day Pro trial, no card required.
Start the trial